These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 8161669)

  • 21. Gastric antisecretory activity of lansoprazole in different experimental models: comparison with omeprazole.
    Coruzzi G; Adami M; Bertaccini G
    Gen Pharmacol; 1995 Sep; 26(5):1027-32. PubMed ID: 7557245
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The long-lasting effect of TU-199, a novel H+, K(+)-ATPase inhibitor, on gastric acid secretion in dogs.
    Uchiyama K; Wakatsuki D; Kakinoki B; Takeuchi Y; Araki T; Morinaka Y
    J Pharm Pharmacol; 1999 Apr; 51(4):457-64. PubMed ID: 10385219
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Role of lipase in the regulation of postprandial gastric acid secretion and emptying of fat in humans: a study with orlistat, a highly specific lipase inhibitor.
    Borovicka J; Schwizer W; Guttmann G; Hartmann D; Kosinski M; Wastiel C; Bischof-Delaloye A; Fried M
    Gut; 2000 Jun; 46(6):774-81. PubMed ID: 10807887
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A comparison of lansoprazole, omeprazole, and ranitidine for reducing preoperative gastric secretion in adult patients undergoing elective surgery.
    Nishina K; Mikawa K; Maekawa N; Takao Y; Shiga M; Obara H
    Anesth Analg; 1996 Apr; 82(4):832-6. PubMed ID: 8615506
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of the effect of lansoprazole in suppressing acid secretion using 24-hour intragastric pH monitoring.
    Takeda H; Hokari K; Asaka M
    J Clin Gastroenterol; 1995; 20 Suppl 1():S7-9. PubMed ID: 7673616
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of the effect of lansoprazole and omeprazole on intragastric acidity and gastroesophageal reflux in patients with gastroesophageal reflux disease.
    Janczewska I; Sagar M; Sjöstedt S; Hammarlund B; Iwarzon M; Seensalu R
    Scand J Gastroenterol; 1998 Dec; 33(12):1239-43. PubMed ID: 9930385
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Proton pump inhibitors in the treatment of peptic ulcers resistant to H2-receptor antagonists].
    Asaka M; Kato M; Sato Y; Miyazaki T
    Nihon Rinsho; 1992 Jan; 50(1):104-10. PubMed ID: 1347322
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Possible mechanisms for (H+ + K+)-ATPase inhibition by proton pump inhibitors, omeprazole, lansoprazole and SCH 28080].
    Nagaya H; Satoh H
    Nihon Rinsho; 1992 Jan; 50(1):26-32. PubMed ID: 1311786
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Double-blind controlled-clinical trials of lansoprazole in the treatment of peptic ulcer].
    Ogawa N
    Nihon Rinsho; 1992 Jan; 50(1):68-73. PubMed ID: 1347332
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Age-related differences in the pharmacokinetics and pharmacodynamics of lansoprazole.
    Hussein Z; Granneman GR; Mukherjee D; Samara E; Hogan DL; Koss MA; Isenberg JI
    Br J Clin Pharmacol; 1993 Nov; 36(5):391-8. PubMed ID: 12959285
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intravenous and oral lansoprazole are equivalent in suppressing stimulated acid output in patient volunteers with erosive oesophagitis.
    Kovacs TO; Lee CQ; Chiu YL; Pilmer BL; Metz DC
    Aliment Pharmacol Ther; 2004 Oct; 20(8):883-9. PubMed ID: 15479360
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pantoprazole versus omeprazole: influence on meal-stimulated gastric acid secretion.
    Dammann HG; Burkhardt F
    Eur J Gastroenterol Hepatol; 1999 Nov; 11(11):1277-82. PubMed ID: 10563540
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Influence of H. pylori infection on meal-stimulated gastric acid secretion and gastroesophageal acid reflux.
    Feldman M; Cryer B; Sammer D; Lee E; Spechler SJ
    Am J Physiol; 1999 Dec; 277(6):G1159-64. PubMed ID: 10600812
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Advantage of expressing the variations in some digestive parameters as a function of gastric emptying instead of time.
    Carrière F; Renou C; Ville E; Grandval P; Laugier R
    Digestion; 2001; 64(1):46-53. PubMed ID: 11549836
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetic interaction between acetaminophen and lansoprazole.
    Sanaka M; Kuyama Y; Mineshita S; Qi J; Hanada Y; Enatsu I; Tanaka H; Makino H; Yamanaka M
    J Clin Gastroenterol; 1999 Jul; 29(1):56-8. PubMed ID: 10405233
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of the enantiomers of lansoprazole (AG-1749) on (H+ + K+)-ATPase activity in canine gastric microsomes and acid formation in isolated canine parietal cells.
    Nagaya H; Inatomi N; Nohara A; Satoh H
    Biochem Pharmacol; 1991 Oct; 42(10):1875-8. PubMed ID: 1660270
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lack of pharmacokinetic interaction after administration of lansoprazole or omeprazole with prednisone.
    Cavanaugh JH; Karol MD
    J Clin Pharmacol; 1996 Nov; 36(11):1064-71. PubMed ID: 8973995
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lansoprazole: a proton pump inhibitor.
    Garnett WR
    Ann Pharmacother; 1996 Dec; 30(12):1425-36. PubMed ID: 8968456
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lansoprazole and omeprazole have similar effects on plasma gastrin levels, enterochromaffin-like cells, gastrin cells and somatostatin cells in the rat stomach.
    Lee H; Håkanson R; Karlsson A; Mattsson H; Sundler F
    Digestion; 1992; 51(3):125-32. PubMed ID: 1355746
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Protection against aspirin-induced gastric lesions by lansoprazole: simultaneous evaluation of functional and morphologic responses.
    Bergmann JF; Chassany O; Simoneau G; Lemaire M; Segrestaa JM; Caulin C
    Clin Pharmacol Ther; 1992 Oct; 52(4):413-6. PubMed ID: 1424414
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.